- Home
- TALO vs KROS Comparison
TALO vs KROS Comparison
Compare TALO & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TALO | KROS |
|---|---|---|
| Founded | 2011 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 565.0M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | TALO | KROS |
|---|---|---|
| Price | $11.21 | $20.73 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 15 |
| Target Price | $14.30 | ★ $22.20 |
| AVG Volume (30 Days) | ★ 2.1M | 1.0M |
| Earning Date | 11-05-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 1.57 |
| Revenue | ★ $1,872,554,000.00 | $246,718,000.00 |
| Revenue This Year | N/A | $6,876.34 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $13.67 |
| Revenue Growth | 0.06 | ★ 37798.31 |
| 52 Week Low | $6.23 | $9.12 |
| 52 Week High | $12.20 | $22.55 |
Technical Indicators
Market Signals| Indicator | TALO | KROS |
|---|---|---|
| Relative Strength Index (RSI) | 51.99 | 63.30 |
| Support Level | $10.64 | $20.73 |
| Resistance Level | $11.96 | $22.20 |
| Average True Range (ATR) | 0.39 | 0.99 |
| MACD | -0.13 | 0.09 |
| Stochastic Oscillator | 36.33 | 68.62 |
Price Performance
Historical ComparisonAbout TALO Talos Energy Inc.
Talos Energy Inc is an independent oil and gas company predominantly involved in offshore exploration and production. The company has operations in the United States, the Gulf of Mexico, and offshore Mexico. The company's operating segments are; exploration and production of oil, natural gas and NGLs, and the CCS segment. The revenue is generated from the sale of oil, natural gas, and NGL quantities sold to purchasers.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.